Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Deferred Taxes (2016 - 2025)

Dexcom (DXCM) has disclosed Deferred Taxes for 16 consecutive years, with $78.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Deferred Taxes rose 1124.68% to $78.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $182.2 million, a 2377.5% increase, with the full-year FY2025 number at $182.2 million, up 2377.5% from a year prior.
  • Deferred Taxes was $78.9 million for Q4 2025 at Dexcom, down from $118.0 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $118.0 million in Q3 2025 to a low of -$85.0 million in Q3 2023.
  • A 5-year average of $5.7 million and a median of $600000.0 in 2021 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: skyrocketed 50400.0% in 2022, then crashed 3583.33% in 2024.
  • Dexcom's Deferred Taxes stood at $15.6 million in 2021, then crashed by 435.26% to -$52.3 million in 2022, then surged by 255.83% to $81.5 million in 2023, then crashed by 109.45% to -$7.7 million in 2024, then skyrocketed by 1124.68% to $78.9 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Deferred Taxes are $78.9 million (Q4 2025), $118.0 million (Q3 2025), and -$17.4 million (Q2 2025).